A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
about
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesRoscovitine in cancer and other diseasesVoltage-gated ion channels in cancer cell proliferationCDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsCurrent classification, treatment options, and new perspectives in the management of adipocytic sarcomasRole of cell cycle regulators in lung carcinogenesisCharacterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell deathCyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.Roscovitine binds to novel L-channel (CaV1.2) sites that separately affect activation and inactivationTargeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastropheCDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.Probing the probes: fitness factors for small molecule tools.The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cellsAntifibrotic effects of roscovitine in normal and scleroderma fibroblasts.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicCdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin ERoscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanismDevelopment of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistancePharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice.The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - RoscovitineRoscovitine confers tumor suppressive effect on therapy-resistant breast tumor cellsR-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repairThe Role of CDK4/6 Inhibition in Breast Cancer.p27(Kip1) is required to maintain proliferative quiescence in the adult cochlea and pituitary.Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability.Roscovitine inhibits CaV3.1 (T-type) channels by preferentially affecting closed-state inactivation.Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complexDual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma.Impact of Tat Genetic Variation on HIV-1 DiseaseCyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-RasBeneficial effects of polydatin on learning and memory in rats with chronic ethanol exposureR-roscovitine reduces lung inflammation induced by lipoteichoic acid and Streptococcus pneumoniae.Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignanciesModulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.New combination therapies with cell-cycle agentsCandidate cancer-targeting agents identified by expression-profiling arrays.CDC25 phosphatases in cancer cells: key players? Good targets?Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model.Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies
P2860
Q21245492-4A81375A-D5D8-422C-BA2B-1D1BC62DE2CFQ26799874-D557C624-6A88-4643-8FCE-380BA6077DBEQ27010511-50E1B974-57A6-46EB-81BC-841F4012D99EQ27670943-98066551-6E98-4431-B94F-CD0595DAA414Q28076210-9FFD4ED7-E5FA-4950-8B9F-AF49C8F81017Q28394676-604156CA-C85D-4EF9-91A1-449F2F894570Q28482928-A7B954F4-FCDF-4CCD-8688-EB9F94747BE5Q33570330-6C8B051D-3E61-4212-AF17-B34B2523083BQ33581333-6FCBDDC4-33ED-4787-94FC-602B2CDE9F45Q33584823-8BB3AA7D-4F2C-4C4C-B8E0-3E8980185404Q33864755-4B35FC77-3423-4857-ADB4-7E3993CB96A3Q33871868-3BDCC853-2441-4FE5-9D52-0C5B6714B12CQ34001269-9E708AD4-176C-4F9F-8C62-CE10DC4BE62FQ34178106-B2649FEB-1736-41AA-89AE-95FF498EA916Q34489708-1FB50257-75CF-473F-832F-13010A5C37C9Q34817365-C08E9275-70A3-41B4-810B-4721337DFB79Q34901237-3CE9EF86-58BD-4264-BDC2-DE5749588CB8Q34954019-FEA1ADDC-FE30-4921-BC0E-FA67A4FA905CQ35000329-AC1F6D71-3726-4619-BF32-7061D565FD4CQ35002296-B6B4B3FD-386C-41C4-A716-1DC55A4D3B32Q35062145-52AA6993-BE9A-4BB5-86EE-CB24EE9A7A4CQ35558138-19747D0D-DAAC-4428-9057-7AE155E14781Q35574807-2BB2959B-CAE0-48BF-9249-B11F7EE30460Q35586728-CFEFD656-443F-4677-80CB-37BBA0DA8D04Q35592149-9A7AA518-B835-4722-BF1F-D117E7F41600Q35613342-9E2A2E49-F7C4-47AE-B21C-3814D67DE447Q35688524-B6FA5D31-D1F4-423B-8F1A-A694C92E9E9BQ35940053-C4C895DD-14E2-4D6D-9015-513AA70FF514Q36140240-47EBB211-B0E3-417A-AFCC-D6CE3489282DQ36148507-F83F368A-D126-47A7-87E3-E854D3136716Q36182661-67577E31-FEF5-4B22-9BF1-1EF10A59EBFDQ36261651-DA58DDBC-71BA-4402-9674-4CAFF58D02E5Q36330067-B58015EE-7B4B-4F56-BA71-037AD8205124Q36579186-FECC791F-9389-4485-8743-10E60E530812Q36709312-90519B39-1273-4777-941F-E548C352090AQ36737314-15791729-D637-4702-AD34-4184381D8E42Q36802115-6AB2FA80-0368-4C37-8D03-682817639FF4Q36849329-51A5A938-4E41-4338-A3A4-5D85D26ECBDCQ36922550-91973B52-944D-400A-949D-29016FAC22C4Q36988173-80348956-98D7-4E9A-9CB2-EEA038C6F3FE
P2860
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A phase I trial of the selecti ...... daily for 7 days every 21 days
@ast
A phase I trial of the selecti ...... daily for 7 days every 21 days
@en
type
label
A phase I trial of the selecti ...... daily for 7 days every 21 days
@ast
A phase I trial of the selecti ...... daily for 7 days every 21 days
@en
prefLabel
A phase I trial of the selecti ...... daily for 7 days every 21 days
@ast
A phase I trial of the selecti ...... daily for 7 days every 21 days
@en
P2093
P2860
P356
P1476
A phase I trial of the selecti ...... daily for 7 days every 21 days
@en
P2093
A Gianella-Borradori
A O'Donnell
C Cruickshank
P2860
P2888
P356
10.1038/SJ.BJC.6603509
P407
P50
P577
2006-12-19T00:00:00Z